DNA

#2377
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
9.5 6 USD
+2.47%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
9.50
9.75
Rango anual
5.37
10.64
Cambio diario
+2.47%
Variación mensual
+27.21%
Variación en los últimos 6 meses
+7.66%
Cambio anual
+7.66%
Cierres anteriores
9.3 3
Open
9.5 9
Mínimo
9.5 0
High
9.7 5
Volumen
204
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 20212022202320242025 TTM

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Noticias